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the Max Planck Society or the FU Berlin, was a highlight. 
The tour showed where the tremendous work by Max
Delbrück, Otto Warburg, Lise Meitner, Otto Hahn, Fritz 
Strassmann and Gerhard Ertl was done, just to mention a 
few.
 The scientific part of the meeting was opened by John 
Hardy from the University College, London, UK, delin-
eating the future developments of genetic analysis in the 
understanding of Alzheimer disease. Besides the analysis 
of loci contributing to the risk of sporadic diseases, ge-
nome-wide association studies will direct towards dis-
tinct genetic variability linked with diseases. Switching 
to the protein level, Peter St. George-Hyslop from the 
University of Toronto, Canada, reported on the enzymat-
ic steps generating A  peptides, the major pathogenic 
agent leading to Alzheimer disease. The main enzyme, 
named   -secretase, shows only enzymatic activity when 
assembled in a complex arrangement of several proteins 
requiring specific interaction motifs, i.e. histidine resi-
dues in certain transmembrane sequences of one subunit. 
Functional protein networks assembled by interaction 
motifs are also central to the research interests of Gerd 
Multhaup from the FU Berlin, Germany. Key molecules 
like APP and BACE1 (  -site APP-cleaving enzyme), 
which are involved in the molecular mechanisms of
Alzheimer disease, form dimers and represent risk fac-
tors for toxic A  formation in their oligomerized forms. 
In addition, he presented evidence that A  peptides may 
have a role in nuclear signaling.
 The molecular basis of Alzheimer disease still holds 
many unsolved secrets. To face those scientific issues, sci-
entists from over 10 different countries met at an Alz-
heimer disease conference in Berlin on September 24–26, 
2009. The venue selected by the organizers Lisa Munter 
and Gerd Multhaup was the brand-new conference hotel 
‘Seminaris’ opened in 2009 on the campus of the Free 
University Berlin (FU Berlin). This campus stands out by 
its unique historical ambiance as at the beginning of the 
20th century numerous Nobel laureates worked there. It 
was the 6th meeting in a row funded by the Luzie Fabisch 
Foundation (box 1). During the meeting, young scientists 
were given plenty of opportunities to discuss topics with 
leading and highly recognized researchers of the field, 
which was reflected by the size of the meeting, with a neat 
number of approximately 60 participants including 24 
speakers. Medical and biochemical topics on signaling in 
Alzheimer and cancer research were combined and ad-
dressed precisely the cutting-edge-of-science issues of 
Alzheimer disease. Intensive discussions dealt with the 
mechanisms affecting processing pathways of key mole-
cules involved in the pathogenesis of Alzheimer disease, 
such as   -amyloid (   ) peptides, amyloid precursor pro-
tein (APP), tau protein and the secretases ( fig. 1 ).
 As part of the social program, Jens-Peter Fürste from 
the FU Berlin provided an enjoyable overview on the sci-
entific history of Berlin-Dahlem. Beyond doubt, the his-
torical walk led by Fürste through the FU campus, passing 
the villa of Fritz Haber and the impressive buildings of the 
former Kaiser Wilhelm Society, which are now owned by 
 Received: March 3, 2010 
 Accepted after revision: May 21, 2010 
 Published online: August 4, 2010 D i s e a s e s
 Lisa-Marie Munter 
 Freie Universität Berlin, Institut für Chemie und Biochemie 
 Thielallee 63 
 DE–14195 Berlin (Germany) 
 Tel. +49 30 8385 2907, Fax +49 30 8385 6509, E-Mail muenter   @   biochemie.fu-berlin.de 
 © 2010 S. Karger AG, Basel
1660–2854/11/0082–0041$38.00/0 




















   
   
   
   
   
   
   
   
   























 APP is a membrane-residing protein with functions 
which are still not well understood. Contributing to the 
solution of this enigma, Daniela Kaden from the FU Ber-
lin, Germany, reported on the impact of metal ions on the 
localization and formation of cell-cell contacts by APP 
and its homologous proteins. The first enzyme in the gen-
eration of Alzheimer-disease-associated A  peptides is 
the   -secretase BACE1, which sheds the ectodomain of 
APP. Alistair Garratt from the Max Delbrück Center for 
Molecular Medicine in Berlin, Germany, focused on sig-
naling events commenced by BACE1 cleavage of neureg-
ulin 1, thereby investigating in vivo functions of BACE1 
besides the generation of toxic A  molecules. APP shed-
ding can also be protective when the members of the 
ADAM (a disintegrin and metalloproteinase) family of 
proteases are active. The presentation by Paul Saftig, 
Christian Albrecht University, Kiel, Germany, provided 
insights into the in vivo function of ADAM10 for APP 
processing in the brain. As he says: ‘The regulation of 
these proteases is complex and still poorly understood. 
Studies in classical and conditional ADAM knockout 
mice revealed their partially redundant roles in angio-
genesis, neurogenesis, tissue development and cancer.’
 After APP has undergone ectodomain shedding, the 
  -secretase complex is the final enzyme to produce A  . 
Particularly, Patrick Fraering from the Brain Mind Insti-
tute, EPFL Lausanne, Switzerland, specified   -secretase 
as ‘an emerging therapeutic target for several types of 
cancer and for Alzheimer disease. To predict cross-reac-
tions and run risk assessments for   -secretase-targeting 
clinical trials, we identified genes and molecular func-
tions transcriptionally susceptible to   -secretase activity 
changes’. Amantha Thathiah from the Catholic Univer-
sity of Leuven, Belgium, reported on a successful high-
throughput functional genomic screen, which identified 
the G-protein-coupled receptor 3 as a novel modulator of 
  -secretase localization and thereby of A  generation.
 The toxicity of A  peptides might be explained by sev-
eral independent pathways. Jacques Hugon from the Uni-
versity Paris 7, France, found that the A  peptide might 
also be involved in translational control. Furthermore, 
Lin Hung from the University of Melbourne, Australia, 
provided evidence that especially dimerized A  peptides 
interact with lipid surfaces and might thereby cause cyto-
toxicity. Lars Lannfelt from Uppsala University, Sweden, 
described soluble A  aggregates as bioactive species by 
using a novel protofibril selective antibody and a mouse 
model carrying the hereditary Arctic mutation in the A  
sequence as well as patient-derived brain material. An-
other A  modification was presented by Thomas Bayer 
from the Georg August University, Göttingen, Germany. 
Based on novel observations from Alzheimer disease pa-
tients’ brains, he developed mouse models generating N-
terminal-truncated and pyroglutamate-modified forms 
of A  and found especially those peptides to cause neuro-
degeneration and concomitant neurological deficits.
 Switching from the laboratory approaches to the clin-
ical level, Christoph Hock from the University of Zürich, 
Switzerland, gave an update on recent developments in 
immunotherapy against A  . He says: ‘Antibodies against 
A  are able to cross the blood-brain barrier and mediate 
clearance from brain by microglia cells. Such interven-
tion should be initiated early in the course of Alzheimer 
disease, ideally prior to the onset of clinical signs of de-



















 Fig. 1. Schematic overview of the topics presented at the meeting. 
Processing of APP and A  generation were main themes; in par-
ticular, genetic variations (No. 1, star) leading to or preventing 
Alzheimer disease were discussed (John Hardy, Nir Barzilai, 
Claudio Franceschi, Michele Mishto). Multiple effects of APP and 
protein oligomerization were reported (No. 2; Gerd Multhaup, 
Daniela Kaden, Michael Schaefer). APP processing is initiated by 
ectodomain shedding (No. 3) by BACE1 or ADAM10, where the 
latter prevents generation of A  indicated in gray (Alistair Gar-
ratt, Paul Saftig, Otmar Huber). Further cleavage of the A  -con-
taining C-terminal stub of APP by   -secretase generates A  pep-
tides, a step that is influenced by additional factors (No. 4; Peter 
St. George-Hyslop, Patrick Fraering, Amantha Thathiah). Vacci-
nation strategies can prevent A  toxicity (No. 5; Christoph Hock). 
A  aggregation causes cytotoxicity (No. 6, illustrated by the cross 
inside the cell; Charles Duyckaerts, Lin Hung, Thomas Bayer, 
Lars Lannfelt). A  peptides might also lead to cell death by other 
effects (No. 7; Jacques Hugon, Jörg Tatzelt, Dietmar Schmitz), and 
also aggregates of the tau protein add to cytotoxicity (No. 8; Luc 
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major role in A  clearance and would deserve more at-
tention in early stages of Alzheimer disease.
 Besides these exciting progressions in the amyloid re-
search field, other proteins involved in aging and Alz-
heimer disease were intensively discussed. Regarding the 
tau protein, Charles Duyckaerts from the Hôpital de la 
Salpêtrière, Paris, France, Luc Buée from the University 
of Lille, France, and Ilse Dewachter from the Catholic 
University of Leuven, Belgium, reported on the impact of 
tau phosphorylation in normal aging, the cognitive de-
cline caused by abnormal tau protein and its relation to 
amyloid pathology. Christian Haass from the Ludwig 
Maximilian University and the ‘Deutsches Zentrum für 
Neurodegenerative Erkrankungen’ in Munich, Germany, 
presented a novel tau model. It is ‘a tau-transgenic fluo-
rescent zebrafish, which displayed a number of the cardi-
nal features of tauopathies. These included abnormal 
phosphorylation and folding of tau, tangle formation, a 
movement phenotype and neuronal cell death. For the 
first time in the field, we were able to monitor cell death 
by in vivo imaging.’ Using this model organism, he also 
found that methylene blue, a drug which was shown to 
slow memory decline in human patients, failed to rescue 
any of the tau-dependent phenotypes. Further, to learn 
from other diseases dealing with aberrant aggregation of 
proteins, Jörg Tatzelt from the Ludwig Maximilian Uni-
versity and the ‘Deutsches Zentrum für Neurodegenera-
tive Erkrankungen’ in Munich, Germany, presented an 
interesting link between the prion protein and A  : ‘In 
prion diseases affecting humans and animals, the cellular 
prion protein (PrPC) is converted into a neurotoxic con-
former designated as PrPSc. We have previously demon-
strated that PrPSc misuses PrPC-dependent signaling 
pathways for neurotoxic signaling. We now present evi-
dence that toxic signaling of soluble oligomers of A  , se-
creted by transfected cells or prepared from chemical 
synthesis, is also dependent on the expression of physio-
logical active PrPC.’ He also showed that dimerization of 
PrPC increases the resistance of cells to stress conditions.
 These contributions on key players in the field of neu-
rodegenerative disorders were complemented by impor-
tant presentations from closely related research fields 
such as cellular signaling of the cadherin/catenin system 
presented by Otmar Huber, Friedrich Schiller University, 
Jena, Germany, or mechanisms of ion channel assembly 
reported by Michael Schaefer from the University of 
Leipzig, Germany. In the fields of electrophysiology and 
neurotransmission, Dietmar Schmitz from the Charité 
Berlin, Germany, highlighted the importance of the mo-
lecular processes at glutamatergic synapses.
 Finally, a session about novel observations derived from 
genetic centenarian trials convinced the auditorium that 
learning from the healthy oldest old might help to under-
stand age-related diseases. Nir Barzilai from the Einstein 
College of Medicine in New York, USA, discussed novel 
mechanisms protecting against age-related decline in cog-
nitive function, Claudio Franceschi from the University of 
Bologna, Italy, presented studies with mitochondrial DNA 
from their centenarian cohorts, and Michele Mishto, 
Charité Berlin, Germany, discussed the meaning of the 
immunoproteasome in neurodegenerative diseases.
 Finally, besides the Luzie Fabisch Foundation the
organizers are grateful to the Verum Foundation (box 2), 
the GRK 1123 and Bruker Daltonics for financial
support. For more information see http://tinyurl.com/
AlzheimerFabisch.
 Box 1 
 Who Was Luzie Fabisch? 
 Luzie Fabisch donated to the Freie Universität Berlin a size-
able sum of money and dedicated it to ‘Cancer Research and 
Cellular Biology’. To give the donation maximum impact, the 
university decided to set it aside for young, not yet settled re-
searchers of the Department of Biology, Chemistry and Phar-
macy, who wish to organize a symposium related to their field 
of research. The leverage of the interest originating from the 
Luzie Fabisch Fund is considerable: in a series of topical sym-
posia, young promising members of the department took ad-
vantage by constituting, without major bureaucratic impedi-
ments, a forum for colleagues working in their respective fields, 
a meeting point for exchange and discussion of data and ideas, 
simultaneously making themselves known as new and active 
members of their community.
 Ferdinand Hucho, honorary chairman of the Luzie Fabisch 
Foundation
 Box 2  
 All participants were asked to vote on the best poster pre-
sented. Poster prizes were funded by the Verum Foundation 
and were awarded to:
   (1) Zoë Goodger, ETH Zürich, Switzerland – ‘  -Cleavage of 
APP in endosomes leads to A  production and nuclear sig-
naling by AICD’, 
   (2) Mohiuddin Quadir, FU Berlin, Germany – ‘Dendritic poly-
glycerol as drug delivery platform for Alzheimer disease’, 
   (3) Janos Steffen, Annett Koch, Elke Krüger, Charité Berlin, 
Germany – ‘The transcription factor TCF11 induces de 
novo formation of proteasomes to compensate for inhibition 
of proteasome activity’, and 
   (4) Heinke Schieb, University of Duisburg-Essen, Germany – 
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